Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioCurex has reported that Inverness Medical Innovations has signed a licensing agreement for BioCurex's RECAF material and technology-based cancer detection products. This agreement is said to help BioCurex move closer towards commercialization of its cancer detection products.
Subscribe to our email newsletter
Under terms of this agreement, Inverness Medical Innovations will have semi-exclusive global rights to commercialize products using the BioCurex-discovered RECAF blood tests for cancer detection. BioCurex will be paid up-front fees, product and development milestones plus royalties on product sales. Inverness will handle FDA approvals, manufacturing, marketing and distributing for clinical laboratory testing.
The patented RECAF technology discovered and developed by BioCurex offers the potential for fast, accurate cancer detection that could significantly prolong the lives of millions of people world-wide.
Ricardo Moro, founder and CEO of BioCurex, said: “This second licensing agreement should also create a more competitive environment among present and future licensees. The first company to offer RECAF blood tests will enjoy a significant marketing and sales advantage — which will be highly beneficial for all concerned.”